by Single-use bioreactors (SUBs) are disposable bioreactor systems used in the commercial manufacturing of biotherapeutic products like monoclonal antibodies, vaccines, stem cells, and gene therapeutics. SUBs offer advantages like lower capital costs, flexibility in production scale, reduced operation and cleaning effort. The global single-use bioreactor market is estimated to be valued at US$ 1337.67 Mn in 2023 and is expected to exhibit a CAGR of 15% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increased R&D investment by biopharma companies in cell and gene therapies has boosted the demand for SUBs in clinical and commercial manufacturing. SUBs are preferred for small-batch production and allow dynamic process development in early R&D stages. Biopharma players are investing heavily in novel therapies and this has necessitated flexible production technologies like SUBs to accelerate clinical development. Their adoption is expected to grow further as cell and gene therapy pipelines mature over the forecast period.
SWOT Analysis
Strength: Single-use bioreactors offer cost and time efficiencies as they require less validation and cleaning efforts compared to stainless steel bioreactors. They are ideal for process development and manufacturing of small batches.
Weakness: Single-use bioreactors are non-reusable which increases the costs associated with purchasing and disposing them. Their performance depends on the lifecycle of individual components.
Opportunity: Growing demand for biopharmaceuticals and emerging biologics is driving the adoption of single-use bioreactors. Advancements in single-use technologies also presents an opportunity for their increased usage in clinical and commercial manufacturing.
Threats: Industry consolidation and compliance to stringent regulatory norms increases entry barriers for new players. Supply chain disruptions and raw material price fluctuations also pose threats.
Key Takeaways
The global Single-Use Bioreactor Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The market size for single-use bioreactor is projected to reach US$ 1337.67 Mn in 2023.
Regional analysis
North America dominates the market currently due to presence of major biopharmaceutical companies and CMOs adopting single-use bioreactors. Asia Pacific is expected to witness fastest growth owing to expansion of biopharma industry in countries like China and India. Increased R&D spending and presence of emerging biosimilars manufacturers are driving the demand.
Key players
Key players operating in the single-use bioreactor market are Sartorius AG, OmniBRx Biotechnologies, Merck KgaA, Solaris Biotechnology Srl, Eppendorf AG, Distek Inc., Celltainer Biotech BV, ABEC Inc., Thermo Fisher Scientific, and Danaher Corporation (Pall Corporation), among others. The major players are focused on capacity expansions and new product launches to strengthen their market position.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, a content writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemicals and materials, etc. With an MBA in E-commerce, she has expertise in SEO-optimized content that resonates with industry professionals.
